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OBJECTIVES: Panic disorder (PD) is an anxiety disorder,
which occurs frequently in patients presenting to a First
Heart Aid (FHA) with chest pain and/or palpitations.
Although the efﬁcacy of pharmacological treatment for
PD in a psychiatric population is high, an accepted stan-
dard treatment for PD in cardiac patients is not yet avail-
able. The objective of this study was to evaluate the
cost-effectiveness of pharmacological treatment com-
pared to care as usual in patients presenting with cardiac
complaints to a FHA in whom PD was conﬁrmed.
METHODS: The design was a randomised double-blind
placebo-controlled study with an intervention group
receiving sertraline or placebo (IG; N = 62) and a care as
usual group (CAUG; N = 44). The study was performed
from the societal perspective with a time horizon of 24
weeks. Costs were calculated using cost diaries and hos-
pital data. Primary endpoint was successful treatment,
deﬁned as reduction of ≥50% of the number of panic
attacks and/or a reduction of ≥50% on the Hamilton
Depression Rating Scale (HAMD). Secondary endpoint
was health state utility, obtained by the EQ-5D, which
was used to calculate QALYs. Incremental cost-effective-
ness ratios (ICERs) were calculated for both endpoints.
Subsequently, bootstrap analyses were performed (1000
replications) to quantify the uncertainty around the
ICERs. RESULTS: Baseline characteristics were compa-
rable for both groups. A total of 67.7% of the patients
in the IG was treated successfully versus 43.2% in the
CAUG (P = .017). Mean QALY in the IG was 0.30, versus
0.29 in the CAUG. The incremental costs amounted to
€-1361.47 (-4060, –1337) in favour of the IG. CON-
CLUSIONS: Based on this preliminary analysis with
unblinded data both ICERs indicated a dominance for IG.
This was conﬁrmed by the bootstrap results, with 84.1%
and 66.7% of the cost-effectiveness pairs, based on
respectively the primary and secondary endpoints, lying
in the southeast quadrant.
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PREVALENCE AND MEDICAL CARE COSTS OF
ANXIETY DISORDERS IN THE UNITED STATES:
A NATIONAL ESTIMATE USING THE MEDICAL
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OBJECTIVES: The objectives of this study were to deter-
mine the prevalence and direct costs of anxiety disorders
in the U.S. population. METHODS: Retrospective analy-
sis was conducted of the 1999 Medical Expenditure Panel
Survey (MEPS). The MEPS collected data from a nation-
ally representative sample of 24,618 respondents and
from respondents’ health care and insurance providers.
Data extracted for this study included medical conditions
and use and payments for medical care. Anxiety disorders
were deﬁned using the current Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV-TR) and were
mapped to corresponding ICD-9-CM codes and included
anxiety and panic disorders, stress disorders, obsessive-
compulsive disorder, and phobias. Anxiety patients were
identiﬁed using ICD-9-CM codes and direct costs were
calculated using patient and third party payments for
anxiety-related medical events by type of medical care.
Sample estimates were weighted and projected to the pop-
ulation and 95% conﬁdence limits were calculated using
the Taylor expansion method. RESULTS: The prevalence
of anxiety disorders was 4.04% or 11,163,423 individu-
als (95% C.L. = 3.64%, –4.44%). Total direct costs of
anxiety disorders were $5,986,529,599. Prescription
medications and ofﬁce-based medical provider visits
accounted for the largest proportions of direct costs, at
$1,963,991,706 (mean = $58; 95% C.L. = $53, –$64)
and $1,890,703,392 (mean = $67; 95% C.L. = $55,
–$79), respectively. Inpatient stays represented
$1,237,191,177 while home health care expenses were
$708,555,879. Emergency department and outpatient
services were each below $140 million. CONCLUSIONS:
Affecting more than 11 million individuals with medical
care costs of almost $6 billion, the impact of anxiety 
disorders was substantial. Prescriptions and medical
provider visits were direct cost drivers, collectively
accounting for more than 60% of total direct costs.
However, expenditures on inpatient stays and home
health care were sizeable, together representing nearly $2
billion or one-third of total direct costs. Additional mea-
sures should be considered to enhance diagnosis and
treatment of anxiety and avert more costly medical care
alternatives.
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OBJECTIVES: The Netherlands Mental Health Survey
and Incidence Study (NEMESIS) is a prospective survey
in the Dutch general population among 7.067 respon-
dents aged 18 to 64. In a follow-up study on the preva-
lence of bipolar disorder (BD) respondents were identiﬁed
by using the Structured Clinical Interview (SCID) result-
ing in a DSM-IV diagnosis for BD. The objective was to
explore the costs to society of BD in the Netherlands. All
available 40 persons identiﬁed with a life-time diagnosis
of BD (DSM-IV) were interviewed. Detailed data on
medical health care utilisation (direct costs) and produc-
tion losses due to absence from work and efﬁciency losses
(indirect costs) as well as quality of life was collected.
METHODS: We used the “Trimbos and iMTA question-
naire on Costs associated with Psychiatric illness (TiC-
P)”. The TiC-P includes a short version of the Health and
Labour questionnaire (HLQ) for collecting data on lost
productivity and efﬁciency losses. For the quality of life
we applied validated generic instruments; the EQ5D of
the EuroQol group and the Short-form 36. RESULTS:
The average direct costs per patient per year was esti-
mated at €897 (range: 0–3200). The average indirect costs
per year was €3720 (range: 0–6373) of which 86% was
due to absence from work. The average score on the
EQ5D was 0.82 (sd 0.2). The quality of life was not sig-
niﬁcantly lower for the BD population compared to the
general population (0.87). Based on the prevalence of
5.2% the total costs of bipolar disorder were estimated
at €1.93 billion (total direct costs = €480 million; total
indirect costs = €1.45 billion). CONLCUSIONS: The
societal costs for bipolar disorder in the Netherlands are
high, especially the indirect costs due to absence from
work. Adequate treatment of bipolar disorder could help
reduce the societal costs and improve patients’ quality of
life.
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OBJECTIVE: To estimate the costs and effects of long-
acting risperidone versus a conventional depot and 
an oral atypical over a 5-year period in Germany.
METHODS: A discrete-event model was developed com-
paring three scenarios. In scenario 1, patients start on
haloperidol depot and may be switched to olanzapine fol-
lowed by clozapine. In scenario 2 patients start on long-
acting risperidone instead of haloperidol depot. In
scenario 3, patients start on olanzapine, and may be
switched to risperidone (oral) followed by clozapine. The
model simulates individual patient histories accounting
for age, gender, type, severity of disease and side effects.
Based on these patient characteristics, the model simu-
lates visits, psychotic episodes, symptom-scores, treat-
ment, compliance and location. Outcomes are expressed
in terms of number and duration of psychotic episodes,
symptom-score and costs. Costs of psychiatrist visits,
medication and location were included. Information was
derived from literature and an expert panel. RESULTS:
Over a 5-year time horizon and per patient, starting with
long-acting risperidone was estimated to avoid 0.21 and
0.32 relapses and to save €131 and €2192 compared to
a conventional depot (scenario 1) and to an oral atypical
(scenario 3) respectively. In subgroup analysis of only
high-risk non-compliant patients starting with long-
acting risperidone was estimated to avoid 0.22 and 0.46
relapses and to save €1442 and €9082. Sensitivity analy-
ses showed that the results are robust and that they are
mainly related to estimates about compliance (when com-
pared to oral atypical agents) and to the effects of atypi-
cal and conventional formulations on the symptom-score.
CONCLUSION: Long-acting risperidone is cost-
effective, as it has higher effectiveness and is cost-neutral
compared to a conventional depot and cost-saving com-
pared to an oral atypical. Further beneﬁts may be
expected, when treatment is aimed at patients with a
high-risk of being non-compliant and at patients in whom
further deterioration is expected.
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OBJECTIVES: Aim of this study was to quantify pro-
duction losses in patients with Borderline Personality Dis-
order (BPD) according to the Human Capital (HC) and
the Friction Costs (FC) methods. METHODS Productiv-
ity levels of BPD-patients were followed for 18 months.
In FC volume was based on the total calendar-period of
absence, irrespective of whether a person was working
part-time or full-time. This is discounted for in the price,
which is based on data from the general working popu-
lation. In FC the price, among other things, also includes
transfer costs. In HC volume was based on actual hours
of absence from work, and price was based on actual pay-
ments. RESULTS: Production losses were €2314 (32 days
¥ €72.31) for FC and €1862 (259 hours ¥ €7.19). CON-
CLUSIONS: Contrary to previous studies, HC results in
lower productivity losses here. Various explanations are
possible. First, in this population, the work pattern is par-
ticularly irregular. The periods of absence are both fre-
quent and short, resulting in repeating friction periods.
Secondly, FC productivity losses are higher when a person
partly resumes work, than when this person remains sick,
which is incorrect from a theoretical point of view. Fur-
